Omeros Corporation
201 Elliott Avenue West
Seattle
Washington
98119
United States
Tel: 206.676.5000
Fax: 206.676.5005
Website: https://www.omeros.com/
Email: hr@omeros.com
About Omeros Corporation
At Omeros, we are proud of our innovative and cutting-edge science. Our world-class team has achieved scientific advances that no other group has been able to accomplish, delivering wholly new classes of therapeutics to benefit patients. We let science lead the way.
From our foundation of groundbreaking science, we continue to build and advance a deep and diverse pipeline of small-molecule and protein therapeutics. We are not interested in developing “me-too” products; instead, we are focused on tackling challenging diseases and disorders with significant unmet medical needs. The result is an exciting pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes.
The Omeros team is exceptionally talented, passionate, collaborative and diverse. We hire smart, creative and hard-working people who want to play a meaningful part in building a preeminent biopharmaceutical company. We come from all corners of the globe, bringing unique abilities and experiences together to provide hope to patients and their families.
458 articles about Omeros Corporation
-
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
3/27/2024
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes.
-
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
2/20/2024
Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
-
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
2/1/2024
Omeros Corporation announced the sale to DRI Healthcare Acquisitions LP, a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.
-
Omeros Corporation Reports Third Quarter 2023 Financial Results
11/9/2023
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2023.
-
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
11/6/2023
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes.
-
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
11/3/2023
Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA.
-
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting - November 2, 2023
11/2/2023
Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 65th Annual Meeting of the American Society of Hematology (ASH), to be held December 9-12, 2023.
-
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
10/19/2023
Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.
-
The biopharma discontinued its late-stage study after an interim review found that its investigational treatment for immunoglobin A nephropathy did not achieve statistically significant improvement over placebo.
-
Omeros Corporation Reports Second Quarter 2023 Financial Results
8/9/2023
Omeros Corporation today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2023.
-
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
8/4/2023
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before the market opens.
-
Omeros Announces Webcast Details for Annual Meeting of Shareholders - June 21, 2023
6/21/2023
Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023, starting at 10:00 a.m. Pacific Time.
-
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
6/12/2023
Omeros Corporation announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association Congress in Frankfurt, Germany are now available on Omeros’ website.
-
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
6/1/2023
Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH) will be shared at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.
-
Omeros Corporation Reports First Quarter 2023 Financial Results
5/9/2023
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2023.
-
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
4/25/2023
Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening hemolytic blood disorder.
-
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
4/10/2023
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).
-
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
3/13/2023
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022.
-
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
3/10/2023
Omeros Corporation, in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.
-
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
3/7/2023
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes.